Skip to main content

Month: August 2023

Essential Oils Market to Worth USD 22.41 Billion by 2030 | At a CAGR of 10.13%

Companies covered in essential oils market are Biolandes SAS (France), Givaudan International SA (Switzerland), International Flavours and Fragrances Inc. (U.S.), Symrise AG (Germany), Enio Bonchev Production Ltd. (Bulgaria), The Lebermuth Company, Inc. (U.S.), Essential Oils of New Zealand (New Zealand), Phoenix Aromas & Essential Oils LLC (U.S.), Sydney Essential Oil Co. (Australia), Young Living Essential Oils (U.S.) & other.Essential Oils MarketEssential Oils MarketPune, India, Aug. 24, 2023 (GLOBE NEWSWIRE) — The global essential oils market size was valued at USD 10.47 billion in 2022 and is projected to grow from USD 11.41 billion in 2023 to USD 22.41 billion by 2030, exhibiting a CAGR of 10.13% during the forecast period. Aetheroleum oils are termed non-water soluble liquids comprising unstable aroma...

Continue reading

Medical Drone Market to Worth USD 3.62 Billion by 2030 | Fortune Business Insights™

The Global Medical Drone Market Covered Major Segments By Type (Fixed Wing, Rotary-Wing, and Hybrid), By Technology (Fully Autonomous, Semi-Autonomous, and Remotely Operated), By Package Size (Less than 2 Kg, 2-5Kg, and More than 5 Kg), By Application (Emergency Blood Logistics, Medical Drug & Vaccine, Emergency Organ Logistics, and Others), and Regional.Medical Drone Market DemandMedical Drone Market OverviewPune, India, Aug. 24, 2023 (GLOBE NEWSWIRE) — The global medical drone market size was valued at USD 1.05 billion in 2022 and is expected to be worth USD 1.25 billion in 2023. The market is projected to reach USD 3.62 billion by 2030, recording a CAGR of 16.4% during the forecast period. A medical drone refers to an unmanned system that can transport large quantities of medical items and other essential supplies....

Continue reading

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights

– Combined full-year revenue and government support income increased 355% year-over-year – – Received guidance from U.S. FDA on a regulatory pathway for its Intelligent Fingerprinting Drug Screening Cartridge – – Granted 13th patent following award of U.K. patent relating to DSR-Plus Cartridge Reader – – Recently secured 8 new customers just two months into product launch in Australia – NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal fourth quarter and full-year ended June 30, 2023, and provided a business update. “In...

Continue reading

Global Veterinary Imaging Market Size to Reach USD 2.83 Billion in 2030 | Emergen Research

Increasing adoption of pets is a key factor driving veterinary imaging market revenue growth Vancouver, Aug. 24, 2023 (GLOBE NEWSWIRE) — The global market for veterinary imaging achieved a valuation of USD 1.65 billion in 2021 and is projected to experience a steady compound annual growth rate (CAGR) of 6.1% throughout the forecast period, as per the latest analysis by Emergen Research. The driving forces behind this upward trajectory encompass factors like the escalating adoption of pets, the heightened prevalence of zoonotic diseases, progressive innovations in veterinary imaging services, and the proactive efforts of governmental entities and animal associations. A pivotal driver in the augmentation of market revenue is the growing adoption of pets. According to publicly available data from the American Society for the Prevention...

Continue reading

Fountain Asset Corp. Announces Its Financial Results for the Quarter Ended June 30, 2023

TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) — Fountain Asset Corp. (TSXV:FA) (“Fountain” or the “Company”) would like to announce its financial results for the three months ended June 30, 2023 (“Q2/23”). Highlights from three months ended June 30, 2023:Net asset value (“NAV”) of $11.00 million ($0.18 per share) at June 30, 2023 compared to $11.68 million ($0.19 per share) at March 31, 2023, representing a decrease of 5.3% quarter over quarter on a per share basis. NAV is calculated as the value of total assets less the value of total liabilities; Net comprehensive loss of $0.70 million for the three months ended June 30, 2023, compared to net comprehensive loss of $5.02 million for three months ended June 30, 2022 (“Q2/22”); Total loss from investment activity was $0.53 million compared to total loss of $4.70 million for Q2/22; Net...

Continue reading

LumiraDx Reports Second Quarter 2023 Results

LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.Second quarter 2023 revenues of $21.0 million Submitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra test Submitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH’s Independent Test Assessment (ITAP) program More than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory seasonRon Zwanziger, Chairman and CEO of LumiraDx, stated, “The submission of our first 510(k) application to the FDA for our COVID Ultra test represents a significant milestone...

Continue reading

Navios Maritime Holdings Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2023

Revenue$81.9 million in Q2 2023 $147.3 million in H1 2023Net Income$15.5 million in Q2 2023 $29.9 million in H1 2023EBITDA, a non-GAAP measure$42.3 million in Q2 2023 $82.8 million in H1 2023GRAND CAYMAN, Cayman Islands, Aug. 24, 2023 (GLOBE NEWSWIRE) — Navios Maritime Holdings Inc. (“Navios Holdings” or the “Company”) (NYSE: NM), today reported its financial results for the second quarter and six months ended June 30, 2023. Navios Holdings owns (i) a controlling equity stake in Navios South American Logistics Inc. (“Navios Logistics”), one of the largest infrastructure and logistics companies in the Hidrovia region of South America and (ii) an interest in Navios Maritime Partners L.P. (“Navios Partners”) (NYSE:NMM), an international shipping company, listed on the New York Stock Exchange, that owns and...

Continue reading

Commercial Display Market to Surpass 81.78 Billion by 2030 Drives Due to Rapid Urbanization

SkyQuest projects that the commercial display market will attain a value of USD 81.78 billion by 2030, with a CAGR of 8.28% over the forecast period (2023-2030). The rapid urbanization witnessed in developing economies has resulted in significant growth in the commercial display market. This growth can be attributed to the continuous development of infrastructure and the changing lifestyles of people. Industries such as retail and hospitality are adopting advanced and digitized promotional approaches to advertise their products and services effectively. Westford, USA, Aug. 24, 2023 (GLOBE NEWSWIRE) — According to SkyQuest, continuous technological advancements have revolutionized the commercial display market, leading to the development of advanced software solutions that enhance audience engagement, people counting and tracking,...

Continue reading

Global Patient Handling Equipment Market Size to Reach USD 18.98 Billion in 2032 | Emergen Research

Increasing government funding and product approvals for healthcare is a key factor driving patient handling equipment market revenue growth Vancouver, Aug. 24, 2023 (GLOBE NEWSWIRE) — The global market size of patient handling equipment attained USD 10.40 Billion in 2022, and it is projected to exhibit a revenue Compound Annual Growth Rate (CAGR) of 6.2% throughout the forecast period, as per the latest analysis conducted by Emergen Research. The escalating prevalence of various diseases, the expanding elderly population, and augmented governmental investments in healthcare constitute the principal drivers underpinning the revenue upsurge in the worldwide patient handling equipment market. Moreover, the progression in medical technology stands as an additional catalyst fostering the expansion of this market. An additional influential...

Continue reading

ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BAUDETTE, Minn., Aug. 24, 2023 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows:Date:   Tuesday, September 12, 2023     Time:   8:30 a.m. ET     Webcast:   Click here     To schedule a 1×1 meeting with the Company, please contact meetings@hcwco.com at H.C. Wainwright. The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.